Engineering and characterization of a divalent single-chain Fv angiotensin II fusion construct of the monoclonal antibody CC49.

For the therapy of solid tumors, co-administration of angiotensin II (AngII) results in an increased uptake of drugs into the tumor interstitium. We have engineered a dimeric sc(Fv)(2)-AngII fusion construct that combines the superior kinetics of covalent dimeric scFvs [sc(Fv)(2)], recognizing the pancarcinoma tumor-associated antigen 72 (TAG-72), with the advantageous intrinsic activity of AngII. The binding characteristics of the fusion construct were unaltered by the addition of the AngII sequence [affinity constant K(A) 1.18 x 10(7) and 8.42 x 10(6) M(-1) for sc(Fv)(2) and sc(Fv)(2)-AngII, respectively]. The binding of the fusion construct to the angiotensin receptor (AT(1)) was similar to AngII, and the arterial contraction was 16 +/- 1% of the response observed with norepinephrine. In animal studies, the radiolabeled sc(Fv)(2)-AngII construct exhibited similar uptake and a more homogeneous distribution within the tumor as compared to sc(Fv)(2).

[1]  S. Batra,et al.  Relative position of the hexahistidine tag effects binding properties of a tumor-associated single-chain Fv construct. , 2000, Biochimica et biophysica acta.

[2]  S. Batra,et al.  Pharmacokinetics and biodistribution of genetically engineered antibodies. , 2002, Current opinion in biotechnology.

[3]  N. Shuke,et al.  Pharmacologic intervention with angiotensin II and kininase inhibitor enhanced efficacy of radioimmunotherapy in human colon cancer xenografts. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[4]  G W Beresford,et al.  Divalent forms of CC49 single-chain antibody constructs in Pichia pastoris: expression, purification, and characterization. , 2000, Journal of biochemistry.

[5]  F. Shishido,et al.  Increased blood flow in human brain tumor after administration of angiotensin II: demonstration by PET. , 1993, Computerized medical imaging and graphics : the official journal of the Computerized Medical Imaging Society.

[6]  S. Batra,et al.  Charge-modified single chain antibody constructs of monoclonal antibody CC49: generation, characterization, pharmacokinetics, and biodistribution analysis. , 1999, Nuclear medicine and biology.

[7]  M. Burton,et al.  Manipulation of experimental rat and rabbit liver tumor blood flow with angiotensin II. , 1985, Cancer research.

[8]  M. Seki,et al.  Intra-arterial infusion chemotherapy in combination with angiotensin II for advanced bladder cancer. , 1986, The Journal of urology.

[9]  S. Ishiguro,et al.  Spiral CT during pharmacoangiography with angiotensin II in patients with pancreatic disease , 1998, Acta radiologica.

[10]  S. K. Imam.  Status of radioimmunotherapy in the new millennium. , 2001, Cancer biotherapy & radiopharmaceuticals.

[11]  P. Carmeliet,et al.  Angiogenesis in cancer and other diseases , 2000, Nature.

[12]  T. Yasuda,et al.  A new method of intra-arterial regional chemotherapy with more selective drug delivery for locally advanced pancreatic cancer. , 1996, Hepato-gastroenterology.

[13]  Sachiko Saito,et al.  Functional characterization of the microcirculation in tumors , 2004, Cancer and Metastasis Reviews.

[14]  Krylova Nv.  Characteristics of microcirculation in experimental tumours. , 1969 .

[15]  D. Kerr,et al.  The effect of angiotensin II on tumor blood flow and the delivery of microparticulate cytotoxic drugs. , 1992, EXS.

[16]  S. Noguchi,et al.  Augmentation of anticancer effect with angiotensin II in intraarterial infusion chemotherapy for breast carcinoma , 1988, Cancer.

[17]  R K Jain,et al.  Effect of transvascular fluid exchange on pressure-flow relationship in tumors: a proposed mechanism for tumor blood flow heterogeneity. , 1996, Microvascular research.

[18]  D. Kerr,et al.  Single photon emission computed tomographic studies (SPECT) of hepatic arterial perfusion scintigraphy (HAPS) in patients with colorectal liver metastases: improved tumour targetting by microspheres with angiotensin II. , 1987, Nuclear medicine communications.

[19]  K. Tokuda,et al.  Modification of tumor blood flow and enhancement of therapeutic effect of ACNU on experimental rat gliomas with angiotensin II , 1990, Journal of Neuro-Oncology.

[20]  D. Hemingway,et al.  The effects of intra-arterial vasoconstrictors on the distribution of a radiolabelled low molecular weight marker in an experimental model of liver tumour. , 1991, British Journal of Cancer.

[21]  H. Shimada,et al.  Enhanced effects of monoclonal antibody carboplatin immunoconjugates uptake and anti-tumor effects with angiotensin II and tumor necrosis factor. , 1999, Journal of chemotherapy.

[22]  K. Hori,et al.  A new approach to cancer chemotherapy: selective enhancement of tumor blood flow with angiotensin II. , 1981, Journal of the National Cancer Institute.

[23]  R. Jain,et al.  Effect of angiotensin II induced hypertension on tumor blood flow and interstitial fluid pressure. , 1993, Cancer research.

[24]  R K Jain,et al.  Microvascular pressure is the principal driving force for interstitial hypertension in solid tumors: implications for vascular collapse. , 1992, Cancer research.

[25]  R K Jain,et al.  Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: significance of elevated interstitial pressure. , 1988, Cancer research.

[26]  S. Batra,et al.  Single-Dose versus fractionated radioimmunotherapy of human colon carcinoma xenografts using 131I-labeled multivalent CC49 single-chain fvs. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[27]  B. Haraldsson,et al.  Transport of macromolecules across microvascular walls: the two-pore theory. , 1994, Physiological reviews.

[28]  R K Jain,et al.  Interstitial hypertension in human breast and colorectal tumors. , 1992, Cancer research.

[29]  Rakesh K Jain,et al.  Lymphatic Metastasis in the Absence of Functional Intratumor Lymphatics , 2002, Science.

[30]  H. Taniguchi,et al.  Angiotensin-II-induced hypertension chemotherapy: evaluation of hepatic blood flow with oxygen-15 PET. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[31]  K. D. Hardman,et al.  In vivo tumor targeting of a recombinant single-chain antigen-binding protein. , 1990, Journal of the National Cancer Institute.

[32]  Dai Fukumura,et al.  Dissecting tumour pathophysiology using intravital microscopy , 2002, Nature Reviews Cancer.

[33]  G W Beresford,et al.  Pharmacokinetics and biodistribution of engineered single-chain antibody constructs of MAb CC49 in colon carcinoma xenografts. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[34]  R K Jain,et al.  Barriers to drug delivery in solid tumors. , 1994, Scientific American.

[35]  B. Axelsson,et al.  Calculation of affinity constants directly from homologous displacement curves. , 1991, Journal of immunological methods.

[36]  G. Tozer,et al.  Modification of tumour blood flow using the hypertensive agent, angiotensin II. , 1993, British Journal of Cancer.

[37]  K. Hori,et al.  Increased Intratumor Concentration of Fluorescein‐isothiocyanate‐labeled Neocarzino‐statin in Rats under Angiotensin‐induced Hypertension , 1988, Japanese journal of cancer research : Gann.

[38]  N. Cheung,et al.  Antibodies against GD2 ganglioside can eradicate syngeneic cancer micrometastases. , 1998, Cancer research.

[39]  J. Schlom,et al.  Radiolocalization of human mammary tumors in athymic mice by a monoclonal antibody. , 1983, Cancer research.

[40]  K. Hori,et al.  Increase in tumor vascular area due to increased blood flow by angiotensin II in rats. , 1985, Journal of the National Cancer Institute.

[41]  M. Burton,et al.  Effect of angiotensin II on blood flow in the transplanted sheep squamous cell carcinoma. , 1988, European journal of cancer & clinical oncology.

[42]  M. Kitao,et al.  Prognostic importance of histologic vascular density in cervical cancer treated with hypertensive intraarterial chemotherapy , 1993, Cancer.

[43]  S. Batra,et al.  Genetically engineered tetravalent single-chain Fv of the pancarcinoma monoclonal antibody CC49: improved biodistribution and potential for therapeutic application. , 2000, Cancer research.

[44]  S. Batra,et al.  Effects of genetic engineering on the pharmacokinetics of antibodies. , 1999, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.

[45]  E. Vitetta,et al.  Immunotoxins: an update. , 1996, Annual review of immunology.

[46]  M F Flessner,et al.  Monoclonal antibody delivery to intraperitoneal tumors in rats: effects of route of administration and intraperitoneal solution osmolality. , 1994, Cancer research.

[47]  K. Sugiyama,et al.  Angiotensin II (AII) induced hypertension chemotherapy (IHC) for unresectable gastric cancer: With reference to resection after down staging , 1995, World Journal of Surgery.